Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTHPomerantz LLP is investigating claims on behalf of investors of Astrana Health, Inc. (“Astrana” or the “Company”) (NASDAQ: ASTH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- Opterion Health gibt positive Ergebnisse der Phase-1-Studie für OPT101 bekannt, die den Übergang zur Phase 2a ermöglichenDie SPARC-Studie hat alle ihre Ziele erreicht und damit eine solide klinische Grundlage für eine differenzierte, nicht auf Glukose basierende Therapie der Peritonealdialyse geschaffen
- Opterion Health 宣布 OPT101 的 1 期临床试验结果积极，支持推进至 2a 期研究SPARC 研究达成全部目标，为差异化、非葡萄糖基的腹膜透析疗法奠定坚实的临床基础
- Hagens Berman Sobol Shapiro LLPBeta Bionics (BBNX) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 3, 2026 Lead Plaintiff DeadlineBeta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025 and February 24, 2026.The lawsuit follows a series of surprise revelations about the FDA's concerns over company's automated insulin delivery system ("iLet"), each of which sent the price of Beta Bionics shares sharply lower. National...
- Nutex Health, Inc.Nutex Health Approved for Dual Listing on Nasdaq TexasNutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX) today announced that it has received approval to dual-list its common stock on Nasdaq Texas. Nutex Health is a physician-led, healthcare services and operations company with 28...
- University of OklahomaA Game Changer: Harold Hamm Commits Largest Gift in OU History to Lift Health of Oklahoma, Name Health CampusThe University of Oklahoma today announced an historic $150 million gift from Harold Hamm, the largest single gift in university history, to lift the health of Oklahoma by advancing health education, research and discovery, strengthening the...
- Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name ChangeHelus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.
- Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTSPomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- MISTR to Fund 2 Million Free HIV & Hepatitis C Tests and Help States Save Hundreds of Millions in ADAP CostsNational initiative will connect patients directly to prevention and treatment while offering states a new model for long-term HIV care at no cost to the state or patient
- Decoy Therapeutics, Inc./C O R R E C T I O N -- Decoy Therapeutics, Inc/In the news release, Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding, issued 22-Sep-2026 by Decoy Therapeutics, Inc over PR Newswire, we are advised by the company that the original version contained incorrect information introduced...
- Deadline Alert: Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026 inclusive (the “Class Period”).
- China Medical Semiconductor Memory Market Report 2026-2032 | Digital Healthcare, AI Diagnostics and Connected Medical Devices Drive Demand"China Medical Semiconductor Memory Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032" has been added to ResearchAndMarkets.com's offering.